We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





Breakthrough Coronavirus Treatment Cures Moderate/Serious COVID-19 Patients within Days

By HospiMedica International staff writers
Posted on 08 Feb 2021
A new coronavirus treatment has helped several moderate-to-serious COVID-19 patients recover from the disease within days in Phase 1 trials, according to a report by The Times of Israel.

The medicine developed by scientists at the Ichilov Medical Center (Tel Aviv, Israel) that moderates immune response and helps prevent deadly cytokine storm allowed 29 out of 30 patients in the trial to leave the hospital within 3-5 days. More...
In what is being hailed as a “huge breakthrough,” all the 30 COVID-19 patients with moderate or worse symptoms who had been administered the EXO-CD24 substance recovered from the disease. The substance uses exosomes, or tiny carrier sacs that shuttle materials between cells, to deliver a protein called CD24 to the lungs in order to fight the cytokine storm and calm down the immune system. The scientists will now begin Phase 2 trial of the medicine which could be a potential game-changer in fighting serious COVID-19 illness.

“The preparation is inhaled once a day for a few minutes, for five days,” Prof. Nadir Arber who discovered the substance told The Times of Israel. “The preparation is directed straight to the heart of the storm - the lungs - so unlike other formulas… which selectively restrain a certain cytokine, or operate widely but cause many serious side effects, EXO-CD24 is administered locally, works broadly and without side effects.”

Related Links:
Ichilov Medical Center


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Xenon Light Source
CLV-S400
Critical Care Conversion Kit
Adapter+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.